{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+therapy+treatment&page=63", "query": { "intervention": "combined therapy treatment", "page": 63 }, "page_size": 10 }, "pagination": { "page": 63, "page_size": 10, "total_count": 12534, "total_pages": 1254, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+therapy+treatment&page=64&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+therapy+treatment&page=62&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T04:13:58.430Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01581138", "title": "VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C Virus" ], "interventions": [ { "name": "VX-222", "type": "DRUG" }, { "name": "telaprevir", "type": "DRUG" }, { "name": "ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 64, "start_date": "2012-07", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2014-07-04", "last_synced_at": "2026-10-26T04:13:58.430Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Anaheim, California • Riverside, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Englewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01581138" }, { "nct_id": "NCT06835283", "title": "Novel Brain Stimulation Treatment for Neuropsychiatric Symptoms in Alzheimer's Disease", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Alzheimer&Amp;#39;s Disease-related Dementia", "Alzheimer Disease", "rTMS Stimulation" ], "interventions": [ { "name": "Brain Stimulation", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "65 Years to 85 Years" }, "enrollment_count": 20, "start_date": "2026-12-01", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-26T04:13:58.430Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06835283" }, { "nct_id": "NCT02779283", "title": "Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Idelalisib", "type": "DRUG" }, { "name": "In Vitro Kinase Inhibitor Assay", "type": "DEVICE" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Methylprednisolone Sodium Succinate", "type": "DRUG" }, { "name": "Ponatinib Hydrochloride", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Ruxolitinib Phosphate", "type": "DRUG" }, { "name": "Sorafenib Tosylate", "type": "DRUG" }, { "name": "Sunitinib Malate", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE", "BIOLOGICAL" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 7, "start_date": "2016-01-13", "completion_date": "2018-09-20", "has_results": false, "last_update_posted_date": "2020-05-26", "last_synced_at": "2026-10-26T04:13:58.430Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02779283" }, { "nct_id": "NCT00001083", "title": "Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Indinavir sulfate", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Nevirapine", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 240, "start_date": null, "completion_date": "2001-06", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-10-26T04:13:58.430Z", "location_count": 58, "location_summary": "Birmingham, Alabama • La Jolla, California • Long Beach, California + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001083" }, { "nct_id": "NCT05660083", "title": "Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-negative Breast Cancer", "Metastatic Breast Cancer", "Metaplastic Breast Carcinoma", "TNBC - Triple-Negative Breast Cancer" ], "interventions": [ { "name": "L-NMMA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2023-01-12", "completion_date": "2028-12-02", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-26T04:13:58.430Z", "location_count": 3, "location_summary": "Bethesda, Maryland • Houston, Texas", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05660083" }, { "nct_id": "NCT01444430", "title": "A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Symbicort pMDI", "type": "DRUG" }, { "name": "budesonide pMDI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "12 Years to 130 Years" }, "enrollment_count": 12460, "start_date": "2011-12", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2016-12-15", "last_synced_at": "2026-10-26T04:13:58.430Z", "location_count": 160, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 157 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01444430" }, { "nct_id": "NCT05304065", "title": "Safe Treatment for Emergency Presentation for Suicidal Ideation and Behavior in Youth", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Suicide", "Suicidal", "Self-Harm" ], "interventions": [ { "name": "SAFETY-A within usual ED Care", "type": "BEHAVIORAL" }, { "name": "Combined SAFETY-A within usual ED Care + CLASP Therapeutic Follow-Up Contacts", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "24 Years", "sex": "ALL", "summary": "13 Years to 24 Years" }, "enrollment_count": 1600, "start_date": "2022-10-17", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-12-31", "last_synced_at": "2026-10-26T04:13:58.430Z", "location_count": 5, "location_summary": "Los Angeles, California • Sylmar, California • Durham, North Carolina + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sylmar", "state": "California" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05304065" }, { "nct_id": "NCT02180867", "title": "Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Alveolar Soft Part Sarcoma", "Angiomatoid Fibrous Histiocytoma", "Atypical Fibroxanthoma", "Clear Cell Sarcoma of Soft Tissue", "Epithelioid Malignant Peripheral Nerve Sheath Tumor", "Epithelioid Sarcoma", "Extraskeletal Myxoid Chondrosarcoma", "Extraskeletal Osteosarcoma", "Fibrohistiocytic Neoplasm", "Fibrosarcoma", "Inflammatory Myofibroblastic Tumor", "Intimal Sarcoma", "Leiomyosarcoma", "Liposarcoma", "Liver Embryonal Sarcoma", "Low Grade Fibromyxoid Sarcoma", "Low Grade Myofibroblastic Sarcoma", "Malignant Peripheral Nerve Sheath Tumor", "Malignant Skin Granular Cell Tumor", "Malignant Triton Tumor", "Mesenchymal Chondrosarcoma", "Myxofibrosarcoma", "Myxoid Chondrosarcoma", "Myxoinflammatory Fibroblastic Sarcoma", "Nerve Sheath Neoplasm", "PEComa", "Pericytic Neoplasm", "Plexiform Fibrohistiocytic Tumor", "Sclerosing Epithelioid Fibrosarcoma", "Skin Glomus Tumor", "Stage IB Soft Tissue Sarcoma AJCC v7", "Stage IIB Soft Tissue Sarcoma AJCC v7", "Stage III Soft Tissue Sarcoma AJCC v7", "Stage IV Soft Tissue Sarcoma AJCC v7", "Synovial Sarcoma", "Undifferentiated High Grade Pleomorphic Sarcoma of Bone" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Pazopanib", "type": "DRUG" }, { "name": "Pazopanib Hydrochloride", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 140, "start_date": "2014-08-12", "completion_date": "2026-03-31", "has_results": true, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-26T04:13:58.430Z", "location_count": 365, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 240 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02180867" }, { "nct_id": "NCT06158100", "title": "Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Donor Lymphocyte Infusion", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Antonio M Jimenez Jimenez", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 2, "start_date": "2024-12-04", "completion_date": "2026-06-02", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-10-26T04:13:58.430Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06158100" }, { "nct_id": "NCT05921292", "title": "Omeza Combination Therapy for the Management and Treatment of Chronic Cutaneous Wounds/Ulcers of Multiple Etiologies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Non-healing Wound", "Non-Healing Ulcer of Skin" ], "interventions": [ { "name": "Omeza Products Used in Combination", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Omeza, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2022-07-11", "completion_date": "2024-05-31", "has_results": false, "last_update_posted_date": "2024-06-21", "last_synced_at": "2026-10-26T04:13:58.430Z", "location_count": 1, "location_summary": "Santa Fe, New Mexico", "locations": [ { "city": "Santa Fe", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT05921292" } ] }